Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) Other Stockholders Equity: NT$539.7 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1762 Chunghwa Chemical Synthesis & Biotech Co Ltd TPE:1762
59 GF Score
Price NT$34.75
GF Value NT$38.65
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Chunghwa Chemical Synthesis & Biotech Co Other Stockholders Equity?

Chunghwa Chemical Synthesis & Biotech Co TPE:1762 +0.72% 59 Other Stockholders Equity is NT$539.7 Mil as of Dec. 2025. GuruFocus rates TPE:1762 with a GF Score™ of 59/100 and a GF Value™ of NT$38.65 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Chunghwa Chemical Synthesis & Biotech Co's Other Stockholders Equity for the quarter that ended in Dec. 2025 was NT$539.7 Mil.

Chunghwa Chemical Synthesis & Biotech Co's quarterly Other Stockholders Equity increased from Jun. 2025 (NT$525.0 Mil) to Sep. 2025 (NT$531.8 Mil) and increased from Sep. 2025 (NT$531.8 Mil) to Dec. 2025 (NT$539.7 Mil).

Chunghwa Chemical Synthesis & Biotech Co's annual Other Stockholders Equity increased from Dec. 2023 (NT$496.0 Mil) to Dec. 2024 (NT$522.5 Mil) and increased from Dec. 2024 (NT$522.5 Mil) to Dec. 2025 (NT$539.7 Mil).

Chunghwa Chemical Synthesis & Biotech Co Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Chunghwa Chemical Synthesis & Biotech Co's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chunghwa Chemical Synthesis & Biotech Co Other Stockholders Equity Chart

Chunghwa Chemical Synthesis & Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 449.07 410.86 496.02 522.50 539.68

Chunghwa Chemical Synthesis & Biotech Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 522.50 533.89 524.97 531.77 539.68
TPE:1762
59GF Score
Chunghwa Chemical Synthesis & Biotech Co Ltd TPE:1762
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chunghwa Chemical Synthesis & Biotech Co Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of NT$539.7 Mil mean?
Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) has a Other Stockholders Equity of NT$539.7 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors.
Is Chunghwa Chemical Synthesis & Biotech Co's Other Stockholders Equity too high?
Chunghwa Chemical Synthesis & Biotech Co's current Other Stockholders Equity is NT$539.7 Mil. Overall, Chunghwa Chemical Synthesis & Biotech Co has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chunghwa Chemical Synthesis & Biotech Co's Other Stockholders Equity compare to VRTX and REGN?
Chunghwa Chemical Synthesis & Biotech Co's Other Stockholders Equity of NT$539.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors. Chunghwa Chemical Synthesis & Biotech Co's current Other Stockholders Equity is NT$539.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chunghwa Chemical Synthesis & Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$38.65, compared to a current price of NT$34.75 — trading 10.1% below its estimated fair value. The current Other Stockholders Equity is NT$539.7 Mil. Chunghwa Chemical Synthesis & Biotech Co's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Chunghwa Chemical Synthesis & Biotech Co (TPE:1762), the current Other Stockholders Equity is NT$539.7 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) Overvalued in 2026?

Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co stock appears to be undervalued. The current stock price of NT$34.75 is trading 10.1% below its estimated GF Value™ of NT$38.65. GuruFocus considers Chunghwa Chemical Synthesis & Biotech Co to be Modestly Undervalued.

Key valuation signals for TPE:1762:

  • Other Stockholders Equity: NT$539.7 Mil
  • GF Value™: NT$38.65 vs. price of NT$34.75 (10.1% below fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the TPE:1762 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chunghwa Chemical Synthesis & Biotech Co Business Description

Address No. 1, Dongxing Street, Shulin District, Taipei, TWN
Chunghwa Chemical Synthesis & Biotech Co Ltd is engaged in the research, development, manufacturing, and sales of pharmaceutical products. Geographically, it derives a majority of its revenue from the United States and also has a presence in Taiwan. Its product portfolio comprises pain management, antifungal, immunosuppressant, oncology, Cardiovascular, Peptide Drugs, and Others.
59GF Score

Get the complete analysis for TPE:1762

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$34.75
Price
NT$38.65
GF Value